StreetInsider.com News Articles

Altimmune to present pemvidutide liver disease data at AASLD 2026

Mon, 19 Oct 2026 08:00:29 -0400

Altimmune, Inc. (Nasdaq: ALT) announced it will present clinical and preclinical data on its investigational drug pemvidutide at the American Association for the Study of Liver Diseases' The Liver Meeting 2026, scheduled for November 5-9, 2026, in Denver, Colorado.

Data from the 48-week IMPACT Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH) showed pemvidutide produced concurrent reductions in liver stiffness, ELF score, liver fat, and alanine aminotransferase compared to placebo. The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3.

Separate IMPACT data showed gastrointestinal adverse events were mild to moderate, with no severe gastrointestinal treatment-emergent adverse events

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Mon, 19 Oct 2026 08:00:00 -0400

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability

Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide

GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Mon, 19 Oct 2026 08:00:00 -0400

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability

Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide

Form 4 Altimmune, Inc. For: Oct 01 Filed by: Arbet-Engels Christophe

Mon, 05 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261005/27148864.html

Form 4 Altimmune, Inc. For: Oct 01 Filed by: WEAVER GREGORY L

Mon, 05 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261005/27148741.html

Form 4 Altimmune, Inc. For: Oct 01 Filed by: MENZIUSO RICHARD THOMAS

Fri, 02 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261002/27142514.html

Form 3 Altimmune, Inc. For: Oct 01 Filed by: MENZIUSO RICHARD THOMAS

Fri, 02 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261002/27142455.html

Form 8-K Altimmune, Inc. For: Sep 24

Tue, 29 Sep 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260929/27117266.html

Altimmune to Participate in Stifel Cardiometabolic Forum

Wed, 23 Sep 2026 08:00:00 -0400

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.

A webcast of the fireside chat will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead

Altimmune to Participate in Stifel Cardiometabolic Forum

Wed, 23 Sep 2026 08:00:00 -0400

A webcast of the fireside chat will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead

Form 4 Altimmune, Inc. For: Sep 16 Filed by: Richardson Linda M

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075843.html

Form 4 Altimmune, Inc. For: Aug 13 Filed by: Durso Jerome Benedict

Thu, 13 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26920747.html

Form 4 Altimmune, Inc. For: Aug 13 Filed by: Durso Jerome Benedict

Thu, 13 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260813/26920747.html

Form 10-Q Altimmune, Inc. For: Jun 30

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912655.html

Form 10-Q Altimmune, Inc. For: Jun 30

Wed, 12 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912655.html

Altimmune, Inc. (ALT) Tops Q2 EPS by 3c

Wed, 12 Aug 2026 07:42:05 -0400

Altimmune, Inc. (NASDAQ: ALT) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

Form 8-K Altimmune, Inc. For: Aug 12

Wed, 12 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26908967.html

Form 8-K Altimmune, Inc. For: Aug 12

Wed, 12 Aug 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260812/26908967.html

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced financial results for the second

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 07:30:00 -0400

Initiated global PERFORMA Phase 3 trial in MASH

Reported positive topline data from RECLAIM Phase 2 trial in AUD

Completed patient enrollment in RESTORE Phase 2 trial in ALD

$519 million in cash, cash equivalents and investments as of June 30, 2026

Webcast to be held today at 8:30 a.m. ET